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ABSTRACT
This community-randomized controlled trial was initiated to assess the overall and herd effects of 2
different human papillomavirus (HPV) immunization strategies in over 80,000 girls and boys aged 12–
15 y in 33 communities in Finland (ClinicalTrials.gov NCT00534638). Overall, 14,838 adolescents received
HPV-16/18 vaccine (2,440 boys and 12,398 girls) and 17,338 received hepatitis-B virus (HBV) vaccine
(9,221 boys and 8,117 girls). In an interim analysis, vaccine safety was assessed by active monitoring and
surveillance via health registry linkage. Active monitoring showed that the HPV-16/18 vaccine has
acceptable safety and reactogenicity in boys. In all study participants, the observed incidences (per
100,000 person-years) of serious adverse events (SAEs) possibly related to vaccination were 54.3 (95%
Conﬁdence Interval [CI]: 34.0–82.1) in the HPV-16/18 group and 64.0 (95% CI: 43.2–91.3) in the HBV
group. During the follow-up period for this interim analysis, the most common new-onset autoimmune
diseases (NOADs; with incidence rate 15 per 100,000) in any group based on hospital discharge
registry (HILMO) download were ulcerative colitis, juvenile arthritis, celiac disease, insulin-dependent
diabetes mellitus (IDDM) and Crohn’s disease. No increased NOAD incidences were observed in
HPV-16/18 vaccine recipients compared to HBV vaccine recipients. In both the SAE possibly related- and
HILMO-analyses, a lower incidence of IDDM was observed in HPV-16/18 vaccinees compared to HBV
vaccinees (relative risks, 0.26 [95% CI: 0.03–1.24] and 0.16 [95% CI: 0.03–0.55], respectively).
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Introduction
Virus-like particle (VLP)-based vaccines against oncogenic, high-
risk human papillomavirus (HPV) types 16 and 18 have been
licensed in most countries, most recently including a 9-valent HPV
vaccine (Gardasil 9 [Merck & Co. Inc.]).1-6 Basis for the licensure
of Cervarix (GSK Vaccines) and Gardasil (Merck & Co., Inc.)
was their acceptable safety proﬁles and vaccine efﬁcacy (VE)
against HPV types 16/18- or 6/11/16/18-related persistent genital
infections and associated cervical intraepithelial neoplasia grade 2/
3 (CIN2/3).7,8 Phase III trial VE estimates for the 2 vaccines appear
similar against HPV types 16 and 18, but differ against CIN3C irre-
spective of HPV type.9 While follow-up trials involving 22,000
young women (aged 16–19 y at the time of ﬁrst vaccination) are
evaluating the long-term safety and efﬁcacy of the 2 vaccines,10,11
recently launched national vaccination programs will provide data
on rare safety outcomes albeit gradually.12-15
The HPV-16/18 vaccine is formulated with the AS04 Adjuvant
System, containing 3-O-desacyl-40-monophosphoryl lipid A
(MPL; 50 mg) adsorbed on aluminum salt (500 mg Al3C), which
has been shown to widely induce T-helper and memory B cell
responses,16 and probably is partially responsible for the wide
cross-protectivity of the vaccine.17,18 However, a theoretical adverse
event of this enhanced immunogenicity might be the induction (or
promotion) of (ongoing) autoimmune processes. The overall and
speciﬁc, with regard to new-onset autoimmune diseases (NOADs),
safety proﬁle of the HPV-16/18 AS04-adjuvanted vaccine has been
acceptable in all ages studied and in combination with other rou-
tine vaccines.19-24 However, to date, safety data have been collected
via conventional reporting of adverse events (AEs) and serious
adverse events (SAEs) in clinical trials, and quantitative safety data
from large cohorts of HPV-16/18 vaccinated adolescents and pop-
ulation-based health registers are sparse.
We report interim safety results for the HPV-16/18 AS04-
adjuvanted vaccine administered to a large cohort of adoles-
cents (ClinicalTrials.gov NCT00534638), with special emphasis
on unique, quantitative population-based health care registry
data on occurrence of NOADs post-vaccination. Study design
and population characteristics have been described in a previ-
ous publication.25 The primary objective of the study is to dem-
onstrate the effectiveness of the HPV-16/18 vaccine in reducing
the prevalence of HPV-16/18 genital infection in females fol-
lowing community-based vaccination of girls and boys 12–15 y
old; these results will be reported in a future publication upon
study and analysis completion.
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Results
Study population
A total of 80,272 adolescents (40,852 boys and 39,420 girls) in
the 1992–1995 birth cohorts were invited to participate in the
study between October 2007 and April 2010, of whom 32,176
(11,661 boys and 20,515 girls) were enrolled and received at
least one dose of study vaccine (Fig. 1). In all, 14,838 adoles-
cents received the HPV-16/18 vaccine (2,440 boys and 12,398
girls) and 17,338 received the HBV vaccine (9,221 boys and
8,117 girls) at 12–16 y of age. Virtually all subjects were white
(Caucasian/European heritage; 99.0%) (Table S1).
Active safety surveillance in males
The male diary card subset comprised 643 subjects who
received HPV-16/18 vaccine and 1,047 who received HBV vac-
cine (Fig. 1). Compliance was high in returning general and
local symptoms sheets (83.5% and 83.3% overall per dose,
respectively, in the HPV-16/18 group and 88.6% and 88.5%,
respectively, in the HBV group). Pain at the injection site was
the most frequently solicited local symptom in both groups
(reported during the 7-day period following 70.4% and 14.0%
of HPV-16/18 and HBV vaccine doses, respectively); fatigue
(31.1% and 21.5%), headache (23.9% and 18.8%) and myalgia
(33.8% and 12.5%) were the most frequently solicited general
symptoms. The rate of local and some general solicited symp-
toms (arthralgia, fatigue, headache and myalgia) appeared
higher among boys who received HPV-16/18 vaccine compared
to those who received HBV vaccine (Fig. 2).
Unsolicited AEs reported in the month following any vac-
cine dose were comparable between HPV-16/18- and HBV-
vaccinated boys (Table 1). During the 30-day post-vaccination
period, 24.4% and 19.3% of boys reported at least one unsolic-
ited symptom after 10.1% and 7.6% of doses in the HPV-16/18
and HBV groups, respectively. Unsolicited AEs considered by
the investigator to be possibly related to vaccination were
reported by 1.9% and 1.8% of boys in the HPV-16/18 and HBV
groups, respectively, after 0.7% and 0.6% of doses.
From Dose 1 to Month 12, in male study participants in the
diary card subset, the proportion of boys with SAEs, SAEs possi-
bly related to vaccination, NOAD and medically signiﬁcant con-
ditions (MSCs) were within the same range in both vaccine
groups (Table 1). SAEs were reported for 1.2% and 2.0% of boys
who received HPV-16/18 and HBV vaccines, respectively. Two
SAEs (IDDM and juvenile arthritis [JA]) were considered possi-
bly related to vaccination by the investigator (blinded to treat-
ment allocation). MSCs were reported by 7.3% of boys for both
vaccines. These were considered possibly related to vaccination
by the investigator in 3 boys (0.5%) who received HPV-16/18
vaccine and 1 boy (0.1%) who received HBV vaccine (concus-
sion, IDDM, JA and oropharyngeal pain; blinded to treatment
allocation). One boy in each group reported an NOAD (IDDM
and JA). Both events were reported as SAEs and were considered
possibly related to vaccination by the investigator.
From Dose 1 to Month 12, in male study participants with
active follow-up, SAEs were reported by 2.4% of boys who received
HPV-16/18 vaccine and 2.0% of boys who received HBV vaccine.
Possible relationship of SAEs with vaccination could not be
excluded in 4 boys (0.2%) who received HPV-16/18 vaccine and 1
boy (0.1%) who received HBV vaccine (abdominal pain, ulcerative
colitis, IDDM and JA; blinded to treatment allocation).
SAEs considered possibly related to vaccination in all study
participants based on active and passive surveillance
During the follow-up period for this interim analysis, the
observed incidence rates (per 100,000 person-years) for SAEs
considered possibly related to vaccination according to the
investigator in all study participants based on active and passive
surveillance were 54.3 (95% conﬁdence interval [CI]: 34.0–82.1)
in the HPV-16/18 group and 64.0 (95% CI: 43.2–91.3) in the
Figure 1. Subject disposition. N, number of subjects; SAE, serious adverse event; AE, adverse event.
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HBV group. The most common SAEs considered possibly
related to vaccination by the investigator (with incidence rate
10 per 100,000 person-years in any group) were ulcerative
colitis, Crohn’s disease, and IDDM. No deaths had been
reported at the time of this interim analysis.
The incidence rates of possibly vaccine-related SAEs were
52.8 (95% CI: 31.3–83.4) and 72.3 (95% CI: 41.3–117.3) in the
HPV-16/18 and HBV groups, respectively, for female study
participants (based on spontaneous reporting and Care Register
for Social Welfare and Health Care [HILMO] data) and 62.1
(95% CI: 16.9–158.9) and 56.6 (95% CI: 30.9–94.9), respec-
tively, for male study participants (based on active surveillance
in a subset of subjects as well as spontaneous reporting and
HILMO data for all subjects).
New-onset autoimmune diseases in all study participants
During the follow-up period for this interim analysis in all study
participants, the most common NOADs (with incidence rate 15
per 100,000 in any group based on the HILMO linkage) were
ulcerative colitis (25.0 and 29.0 cases per 100,000 person years in
the HPV-16/18 and HBV groups, respectively), juvenile arthritis
(22.2 and 26.6 cases per 100,000 person years, respectively), celiac
disease (16.7 and 26.6 cases per 100,000 person years, respectively),
IDDM (8.3 and 50.7 cases per 100,000 person years, respectively),
and Crohn’s disease(8.3 and 16.9 cases per 100,000 person years,
respectively). Of note, no cases of Guillain-Barre syndrome were
observed, and other NOADs were found only occasionally in both
vaccine groups. In terms of numbers of cases, IDDMwas the most
common NOAD diagnosis identiﬁed in the HILMO linkage
(3 cases in the HPV-16/18 group and 21 in the HBV group).
Almost all the 95% CIs of relative risk (RR) estimates for the inci-
dent NOAD cases in the HPV-16/18 group as compared to the
HBV group included unity (Fig. 3), with the exception of IDDM
(RR: 0.16, 95% CI: 0.03–0.55). A decreased relative risk of IDDM
was observed both for females (2 vs. 7 cases; RR: 0.19, 95% CI:
0.02–0.97) and males (1 vs. 14 cases; RR: 0.27, 95% CI: 0.01–1.8)
(Table S2).
The incidences of the most common NOADs identiﬁed by
the HILMO linkage (i.e., medical history-conﬁrmed) and by
Figure 2. Incidence of solicited local and general symptoms reported during the 7-day post-vaccination period (Days 0–6) following any vaccine dose (male study partici-
pants in the male diary card subset, total vaccinated cohort). Occurrence of rash and urticaria within 30 minutes following vaccination.
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SAE reporting are shown in Table 2. More cases were recorded
in the HILMO registry (Table 2).
Pregnancies in all female study participants
A total of 174 pregnancies had been spontaneously reported at
the time of this interim analysis (100 in girls who received
HPV-16/18 vaccine and 74 in girls who received HBV vaccine).
The majority of pregnancies resulted in elective termination
with no apparent congenital anomaly (60 [60.0%; 95%
CI: 49.7–69.7] and 52 [70.3%; 95% CI: 58.5–80.3] for the 2 vac-
cines, respectively) or in a live infant (no premature birth) with
no apparent congenital anomaly (30 [30.0%; 95% CI:
21.2–40.0] and 20 [27.0%; 95% CI: 17.4–38.6], respectively).
Spontaneous abortions before 22 weeks of gestation (with no
apparent congenital anomaly) were reported in 7 girls who
received HPV-16/18 vaccine versus 2 girls who received HBV
vaccine (7.0% [95% CI: 2.9–13.9] vs. 2.7% [95% CI: 0.3–9.4];
RR: 2.59 [95% CI: 0.55–12.11]). No stillbirths, therapeutic abor-
tions, ectopic pregnancies and molar pregnancies were
reported. At the time of the reported analysis, 2 pregnancies
were still ongoing in girls who received HPV-16/18 vaccine.
Complete pregnancy data from medical birth registries will
be available at the time of ﬁnal analysis.
Discussion
Sizeable cluster-randomized phase IV trial cohorts, enrolled in a
population-based fashion, are now available for studies on the
effectiveness and safety of HPV-16/18 vaccination. These popula-
tion-based cohorts provide unique health registry-based, quantita-
tive data on the safety of the HPV-16/18 AS04-adjuvanted vaccine
and the HBV vaccine. This large community-randomized study
assessed the safety of HPV-16/18 vaccination in early adolescents,
providing relative risk estimates on the occurrence of NOADs in
the 2 vaccine arms over 2–3 y of follow-up.We found that themed-
ical record-conﬁrmed IDDM incidence in HPV-16/18 vaccinees
was lower than that in HBV vaccinees. The incidence of IDDM
seen in HPV-16/18 vaccinees in this study is also lower than that
reported in somewhat younger, 10–14 year-old Finns (50.4 per
100,000).26 Our observation, and a signiﬁcantly decreased inci-
dence rate ratio for IDDM (0.55) in approximately 190,000 females
that has also been reported following HPV-6/11/16/18 vaccina-
tion,27 suggest that the possible role of HPVs in IDDM warrants
further investigation. The possibility, that the HPV VLP vaccines
and/or the AS04-adjuvant of theHPV-16/18 vaccine provide unex-
pected protection against IDDM, e.g., by delaying/re-directing an
already ongoing autoimmune process, should also be explored.
Figure 3. Estimated relative risk of the occurrence of new-onset autoimmune disease (NOADs) with 95% conﬁdence interval, classiﬁed by MedDRA primary system organ
class and preferred term, during the entire study period (all study participants, total vaccinated cohort). Dots represent point estimates. NOADS which occur in only one
group remain blinded and are therefore not shown in this ﬁgure.
Table 1. Active safety surveillance from Month 0–Month 12 (male dairy card sub-
set, total vaccinated cohort). Incidence of unsolicited symptoms (most frequent
symptoms listed), serious adverse events, medically signiﬁcant conditions and
new-onset autoimmune diseases.
HPV-16/18 vaccine
(N = 643)
HBV vaccine
(N = 1047)
n % (95% CI) n % (95% CI)
Within 30 d (Days 0–29) following any vaccine dose
Unsolicited symptoms 157 24.4 (21.1–27.9) 202 19.3 (16.9–21.8)
Nasopharyngitis 33 5.1 (3.6–7.1) 17 1.6 (0.9–2.6)
Headache 23 3.6 (2.3–5.3) 16 1.5 (0.9–2.5)
Oropharyngeal pain 15 2.3 (1.3–3.8) 32 3.1 (2.1–4.3)
Pyrexia 17 2.6 (1.5–4.2) 21 2.0 (1.2–3.0)
Upper RTI 13 2.0 (1.1–3.4) 3 0.3 (0.1–0.8)
Vaccine-related 12 1.9 (1.0–3.2) 19 1.8 (1.1–2.8)
Up to Month 12 after ﬁrst vaccine dose
Serious adverse events 8 1.2 (0.5–2.4) 21 2.0 (1.2–3.0)
Vaccine-related 1 0.2 (0.0–0.9) 1 0.1 (0.0–0.5)
Medically signiﬁcant conditions 47 7.3 (5.4–9.6) 76 7.3 (5.8–9.0)
New onset autoimmune diseases 1 0.2 (0.0–0.9) 1 0.1 (0.0–0.5)
N, total number of male subjects; n (%), number (percentage) of male subjects
with at least one symptom; HPV vaccine, HPV-16/18 AS04-adjuvanted vaccine;
HBV, hepatitis B virus vaccine; RTI, respiratory tract infection.
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As for other NOADs, except those that remained blinded at the
time of this analysis, we observed no apparent difference in the
incidence of overall medical record-conﬁrmed or possibly related
occurrence estimates between the 2 vaccination arms. This is in
line with comparable health registry-based ﬁndings on the HPV-6/
11/16/18 vaccine.28 The health registry-based surveillance was
more sensitive than the conventional SAE surveillance. This kind
of health registry-based quantitative analysis is an important
adjunct to the safety data on the HPV-16/18 vaccine and will in the
future continue to be most appealing to health authorities in the
context of newly licensed vaccines for suspected or alleged vaccine-
associated adverse effects (e.g., autism, narcolepsy) or in the case of
HPV vaccination, primary ovarian failure syndrome29 or miscar-
riage.23,30-32
Both active and passive safety surveillance in this trial showed
that the HPV-16/18 vaccine has an acceptable safety and reacto-
genicity proﬁle in boys, which is similar to the results of other
studies of this vaccine in adolescent girls24,33 and boys.34
Strengths of our study were uniform enrolment of the early
adolescents by school year and birth cohort and community,
retaining the participants in the follow-up phase, and popula-
tion-based health registry follow-up. Analysis of questionnaire
data for the study participants showed no differences in
behavioral or health conscience characteristics between the 2
vaccine groups.25 The differential blinding used in the study is
a potential limitation, mainly for the active surveillance. Other
limitations include the imbalance in gender distribution
between the 2 vaccine groups (83.6% of vaccinees were female
and 16.4% were male in the HPV-16/18 vaccine group com-
pared with 46.8% and 53.2%, respectively, in the HBV vaccine
group). In addition, safety data were collected via different
methods of surveillance, including active surveillance in a sub-
set of male study participants (using diary cards and phone
calls) and surveillance of NOADs in all study participants based
on download from the national heath registry (HILMO). The
follow-up time for safety endpoints varied for the different sur-
veillance methods and also within subjects for surveillance
based on registry download. The HILMO database is one of the
most important registers used in healthcare research in Fin-
land.35 This database receives annually (by law) discharge
information from all hospitals in the country, including both
inpatient and outpatient services. However, it should be noted
that the case assessment of HILMO-retrieved NOADs was
based on the review of medical records which did not always
provide all sufﬁcient information for assessment of autoim-
mune diseases. Finally, analysis of safety was planned to be
descriptive and no correction for multiplicity was applied.
Study ﬁndings should therefore be interpreted with caution.
Table 2. Incidence (per 100,000 person years) and relative risk of major NOADs in all study participants (total vaccinated cohort) based on active and passive surveillance
and registry analysis.
HPV-16/18 vaccine All HBV vaccine All Relative risk (HPV/HBV) (95% CI)
Category Case identiﬁcation
No.
cases
Incidence
(105) (95% CI)
No.
cases
Incidence
(105) (95% CI) All Femaled Maled
Henoch-Schonlein purpura Registry alla 2 5.6 (0.7–20.1) 2 4.8 (0.6–17.5) 1.15 (0.08–15.87) 1.3 (0.07–76.47) na
Registry 12 mb 2 9.3 (1.1–33.7) 1 4.0 (0.1–22.2) 2.34 (0.12–138.23) 1.31 (0.07–77.42) na
SAE possibly-relatedc 1 2.5 (0.1–13.7) 1 2.1 (0.1–11.9) 1.16 (0.01–90.77) 0.65 (0.01–50.96) na
Idiopathic thrombocytopenic
purpura
Registry alla 3 8.3 (1.7–24.4) 4 9.7 (2.6–24.7) 0.86 (0.13–5.10) 0.97 (0.11–11.64) na
Registry 12 mb 1 4.7 (0.1–26.0) 2 8.0 (1.0–28.8) 0.59 (0.01–11.25) 0.33 (0.01–6.3) na
SAE possibly-relatedc 1 2.5 (0.1–13.7) 1 2.1 (0.1–11.9) 1.16 (0.01–90.77) 0.65 (0.01–50.96) na
Autoimmune thyroiditis Registry alla 3 8.3 (1.7–24.4) 1 2.4 (0.1–13.5) 3.45 (0.28–181.16) 1.94 (0.16–102.07) na
Registry 12 mb 3 14.0 (2.9–40.9) 1 4.0 (0.1–22.2) 3.51 (0.28–184.51) 1.97 (0.16–103.34) na
SAE possibly-relatedc 1 na 1 na na na na
Celiac disease Registry alla 6 16.7 (6.1–36.3) 11 26.6 (13.3–47.5) 0.63 (0.19–1.85) 0.56 (0.15–1.93) na
Registry 12 mb 3 14.0 (2.9–40.9) 8 31.9 (13.8–62.8) 0.44 (0.08–1.83) 0.39 (0.06–2.02) na
SAE possibly-relatedc — na — na na na na
Ulcerative colitis Registry alla 9 25.0 (11.4–47.5) 12 29.0 (15.0–50.6) 0.86 (0.32–2.23) 1.13 (0.29–5.28) 0.96 (0.1–4.8)
Registry 12 mb 6 28.0 (10.3–61.0) 9 35.9 (16.4–68.1) 0.78 (0.23–2.46) 0.82 (0.18–4.13) 0.77 (0.02–6.86)
SAE possibly-relatedc 5 12.3 (4.0–28.8) 3 6.4 (1.3–18.7) 1.93 (0.37–12.41) 1.3 (0.19–14.35) 3.84 (0.05–301.44)
Crohn’s disease Registry alla 3 8.3 (1.7–24.4) 7 16.9 (6.8–34.8) 0.49 (0.08–2.16) 1.94 (0.16–102.07) na
Registry 12 mb 2 9.3 (1.1–33.7) 5 19.9 (6.5–46.5) 0.47 (0.04–2.86) 1.31 (0.07–77.42) na
SAE possibly-relatedc 1 2.5 (0.1–13.7) 5 10.7 (3.5–24.9) 0.23 (0.00–2.07) 0.65 (0.01–50.96) na
IDDM Registry alla 3 8.3 (1.7–24.4) 21 50.7 (31.4–77.5) 0.16 (0.03–0.55) 0.19 (0.02–0.97) 0.27 (0.01–1.8)
Registry 12 mb 3 14.0 (2.9–40.9) 8 31.9 (13.8–62.8) 0.44 (0.08–1.83) 0.26 (0.02–1.6) 1.28 (0.02–15.93)
SAE possibly-relatedc 2 4.9 (0.6–17.8) 9 19.2 (8.8–36.4) 0.26 (0.03–1.24) 0.16 (0–1.64) 0.77 (0.02–6.86)
Juvenile arthritis Registry alla 8 22.2 (9.6–43.8) 11 26.6 (13.3–47.5) 0.84 (0.29–2.28) 0.49 (0.14–1.6) 2.56 (0.21–22.31)
Registry 12 mb 7 32.7 (13.1–67.3) 11 43.8 (21.9–78.4) 0.75 (0.25–2.11) 0.41 (0.11–1.42) 2.56 (0.21–22.33)
SAE possibly-relatedc 3 na 3 na na na na
Rheumatoid arthritis Registry alla 1 2.8 (0.1–15.5) 2 4.8 (0.6–17.5) 0.58 (0.01–11.05) 0.32 (0.01–6.22) na
Registry 12 mb 1 4.7 (0.1–26.0) 1 4.0 (0.1–22.2) 1.17 (0.01–91.96) 0.66 (0.01–51.51) na
SAE possibly-relatedc 1 na 1 na na na na
ahealth register-identiﬁed, medical record-conﬁrmed cases diagnosed post 1st vaccine dose during the entire study period (all study participants, total vaccinated cohort);
35,992 and 41,401 follow-up years in the HPV-16/18 and HBV groups, respectively
bhealth register-identiﬁed, medical record-conﬁrmed cases diagnosed within 12 months after last vaccination (all study participants, total vaccinated cohort); 21,422 and
25,097 follow-up years in the HPV-16/18 and HBV groups, respectively
cSAE cases considered possibly related to vaccination during the entire study period (all study participants, total vaccinated cohort); 40,552 and 46,890 follow-up years in
the HPV-16/18 and HBV groups, respectively.
n, total number of cases reported, information is blinded since the study is ongoing
HPV-16/18 vaccine, HPV-16/18 AS04-adjuvanted vaccine; HBV, hepatitis B virus vaccine; IDDM, insulin-dependent diabetes mellitus ; na, not available; 12 m, 12 months;
95% CI, 95% conﬁdence interval
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With the current follow-up mode, our community-random-
ized phase IV trial will continue to provide population-based
safety data (e.g. on chronic diseases, pregnancy outcomes) for
the HPV-16/18 vaccine.
Materials and methods
Study design
This study was conducted in 33 major, non-adjacent Finnish
communities as previously described.25 All 80,272 Finnish or
Swedish speaking boys and girls in the 1992–1995 birth cohorts
in these communities were invited by letter to participate in the
trial. The communities were stratiﬁed into 3 groups according
to HPV-16/18 seroprevalence (low, <20.5%; intermediate,
20.5–24.0%; high, >24.0%). Within each seroprevalence group,
communities were randomly assigned in equal numbers to one
of 3 intervention arms using a random number generator. In
Arm A communities, 90% of participating girls and boys
received HPV-16/18 vaccine and 10% received hepatitis B virus
(HBV) vaccine (EngerixTM B, GSK Vaccines); in Arm B com-
munities, 90% of girls received HPV-16/18 vaccine and 10% of
girls and 100% of boys received HBV vaccine; in Arm C com-
munities, 100% of girls and boys received HBV vaccine. The
9:1 ratio used to allocate study participants from Arms A
(males and females) and B (females only) was determined to
target an HPV vaccination coverage of approximately 70%
within adolescent resident in these communities, considering
that 85–90% of study participants would meet admission crite-
ria and that approximately 90% of them would agree to
participate in the immunization phase. Treatment allocation at
investigator sites was performed using a central internet-based
randomization system. Vaccine doses were administered at
Months 0, 1 and 6 at schools by the same study nurses during
school years 2007–2008, 2008–2009 and 2009–2010. Although
the study was open at community level because different vacci-
nation strategies were used between Arms (for primary objec-
tives), blinding was maintained for all subjects in Arm A and
for girls in Arm B in order to reduce bias for both safety and
effectiveness analysis.
The study was approved by a regional independent ethics
committee and conducted in accordance with good clinical
practice (GCP) and all applicable regulatory requirements,
including the Declaration of Helsinki. Subjects aged <15 y pro-
vided written informed assent prior to the performance of any
study-speciﬁc procedures; written informed consent was also
obtained from participants’ parents or legal representatives.
Written informed consent was obtained from study partici-
pants aged 15 years.
Safety reporting
A combination of active and passive safety surveillance was
performed according to intervention arm (Fig. 4). As the study
was conducted while the HPV-16/18 vaccine was not licensed
for use in males, it was designed to provide important safety
information in males in order to complement the already sub-
stantial safety data available in women. Therefore, a subset of
boys from Arm A and Arm C communities was selected for
active assessment of safety using diary cards (male diary card
Figure 4. Overview of safety assessments within intervention arms. In Arm A, 90% of boys and girls received HPV-16/18 vaccine and 10% received HBV vaccine. In Arm B,
90% of girls received HPV-16/18 vaccine and 10% of girls and all boys received HBV vaccine. In Arm C, all girls and boys received HBV vaccine. DC, diary card; M, month;
MSC, medically signiﬁcant conditions; NOAD, new-onset autoimmune diseases; PS, passive surveillance including reporting of possibly vaccine-related SAEs and NOADs
based on registry download; SAEs, serious adverse events.
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subset). The size of the eligible population was the main consid-
eration for the selection of the communities for the diary card
subset. These subjects were to record solicited local and general
symptoms within 7 d (Days 0–6) and unsolicited AEs within
30 d (Days 0–29) after each vaccination. The investigator
recorded any occurrence of rash and/or urticaria within
30 minutes following each vaccination. These subjects were
also actively questioned at Months 7 and 12 about any MSCs
(including NOADs) and SAEs that might have occurred after
the ﬁrst vaccination. Active safety surveillance for the occur-
rence of SAEs was also performed in boys from Arm A com-
munities who were not included in the diary card subset at
Months 7 and 12. A SAE was any untoward medical occurrence
that resulted in death, was life-threatening, required hospitali-
zation or prolongation of existing hospitalization, resulted in
disability or incapacity, or was a congenital anomaly or birth
defect in the offspring of a study participant.
Passive safety surveillance was performed for all subjects in all
intervention arms throughout the study period up to the cut-off
date for this interim analysis. Any SAEs reported to the investigator
considered possibly related to vaccination and pregnancy outcomes
were reported using a remote data entry system at the study sites
and/or at the junior high-schools. For the HILMO-based analysis
(Fig. S1), the study participants had consented for personal identity
code (PIC)-based linkages of the Registry of Vaccinated Individuals
(RVI) and the HILMO. The RVI and HILMO registry linkage for
predeﬁned NOADs (Table S3) was performed after the HILMO
registry had been completed for the 2010 diagnostic (ICD-10
encoded) data on all outpatient and inpatient visits in Finland.
Thus, depending on the time of enrolment, there were approxi-
mately 1–3 y of registry-based follow-up data available for the differ-
ent birth cohorts for the predeﬁned NOADs after administration of
the ﬁrst vaccine dose (fromOctober 2007 to December 2010 for the
1992–1993 birth cohorts and from August 2008 to December 2010
for the 1994–1995 birth cohorts). The HILMO register is virtually
complete for all the outpatient and inpatient ICD-10 diagnoses
made by Finnish healthcare since 2000 and 1996, respectively.35
The cases identiﬁed in the register linkage were conﬁrmed bymedi-
cal history data, which were obtained based on the informed con-
sent from the hospitals and hospital municipal health centers. The
most important consideration for not excluding possible causality
was temporal association, namely onset within 18 months from the
ﬁrst vaccine dose (i.e., approximately 12 months from the last vac-
cine dose). For the NOAD assessment, the investigator was blinded
to both vaccination and community status.
Statistical analyses
This was a planned interim analysis, which was initiated after
completion of the Month 12 active surveillance, and was con-
ducted when Month 12 passive surveillance data for subjects
enrolled by the end of 2009 were available. The current report
presents the safety data recorded up to April 2011 in all male
and female study participants. The primary population for the
analysis of safety was the total vaccinated cohort. For the male
diary card subset, the overall percentage of doses with any and
grade 3 solicited local and general symptoms were calculated.
The percentage of subjects with unsolicited AEs (within 30 d
following any vaccine dose) and with SAEs, MSCs and NOADs
(up to Month 12 after ﬁrst vaccine dose) were also calculated.
For all study participants (active and passive surveillance com-
bined), the incidence rates (per 100,000 person-years) of sub-
jects with at least one report of SAE with relationship to
vaccination over the duration of follow-up for this interim
analysis, was calculated with exact 95% CI, together with RR
(and 95% CI). The incidence rate (per 100,000 person-years) of
study participants with at least one report of NOAD classiﬁed
by MedDRA was calculated with exact 95% CI, together with
RR (and 95% CI), both for the entire duration of follow-up for
this interim analysis and for the 12-month period after admin-
istration of the last vaccine dose. Relative risks (and 95% CI) as
well as 95% CIs around frequency of pregnancy outcomes were
calculated in a post-hoc analysis.
Trademark statement
Cervarix is a registered trademark of the GSK group of compa-
nies. Engerix-B is a trademark of the GSK group of companies.
Highlights
 As seen in girls, the HPV-16/18 vaccine has acceptable
safety/reactogenicity in boys
 Similar rates of possibly related serious adverse events for
HBV and HPV-16/18 vaccines
 Low incidence of insulin-dependent diabetes mellitus
seen in HPV-16/18 vaccinees
 Small number of cases observed for most other new-onset
autoimmune diseases
 No apparent differences in incidences of other autoim-
mune diseases between vaccines
Abbreviations
AE adverse event
CI conﬁdence interval
CIN cervical intraepithelial neoplasia
HBV hepatitis B virus
HILMO Care Register for Social Welfare and Health Care
HPV human papillomavirus
ICD-10 International Classiﬁcation of Diseases-10
IDDM insulin-dependent diabetes mellitus
JA juvenile arthritis
MPL 3-O-desacyl-40-monophosphoryl lipid A
MSC medically signiﬁcant condition
NOAD new-onset autoimmune disease
pIMD potential immune-mediated disease
RR relative risk
SAE serious adverse event
VE vaccine efﬁcacy
VLP virus-like particle
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